- Home
- ROIV vs MTZ Comparison
ROIV vs MTZ Comparison
Compare ROIV & MTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | MTZ |
|---|---|---|
| Founded | 2014 | 1929 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Water Sewer Pipeline Comm & Power Line Construction |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 13.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ROIV | MTZ |
|---|---|---|
| Price | $21.70 | $220.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 20 |
| Target Price | $21.94 | ★ $228.89 |
| AVG Volume (30 Days) | ★ 6.7M | 846.2K |
| Earning Date | 11-10-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 270.77 |
| EPS | N/A | ★ 4.20 |
| Revenue | $20,329,000.00 | ★ $13,762,473,000.00 |
| Revenue This Year | N/A | $15.48 |
| Revenue Next Year | $376.94 | $10.21 |
| P/E Ratio | ★ N/A | $52.65 |
| Revenue Growth | N/A | ★ 12.99 |
| 52 Week Low | $8.73 | $99.70 |
| 52 Week High | $22.45 | $233.14 |
Technical Indicators
Market Signals| Indicator | ROIV | MTZ |
|---|---|---|
| Relative Strength Index (RSI) | 62.44 | 58.05 |
| Support Level | $20.14 | $218.48 |
| Resistance Level | $21.48 | $233.14 |
| Average True Range (ATR) | 0.71 | 7.84 |
| MACD | 0.00 | 1.22 |
| Stochastic Oscillator | 65.96 | 62.28 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About MTZ MasTec Inc.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.